The neurological benefits of Photobiomodulation therapy (PBMT), often called red light therapy or near-infrared (NIR) light therapy, delivers specific wavelengths of red and near-infrared light (typically in the 600–1100 nm range) to tissues. When applied to the head (transcranial PBMT or tPBM), this non-invasive approach is being studied for its effects on brain health. Light is absorbed by cytochrome c oxidase in mitochondria, supporting ATP production, reducing oxidative stress and inflammation, improving cerebral blood flow, promoting neurogenesis and synaptic plasticity, and in some models enhancing glymphatic clearance of waste products. For more information and clinical based research, click HERE!
Early evidence spans neurodegenerative conditions, neurodevelopmental concerns, traumatic brain injury (TBI), mood disorders, and cognitive performance in both clinical and healthy populations. Most human studies remain small or preliminary, and larger randomized controlled trials are still needed. PBMT is generally well-tolerated with a strong safety profile in published reports, but it is not a proven cure for any neurological condition.
Neurological Benefits: Dementia and Alzheimer’s Disease
Preclinical work in Alzheimer’s models consistently shows reductions in amyloid-beta plaques and hyperphosphorylated tau, decreased neuroinflammation, improved mitochondrial function, enhanced cerebral perfusion, and better cognitive performance in animals. Mechanisms under investigation include microglial modulation, increased BDNF, and improved glymphatic drainage.
Human data are encouraging but limited. A 2017 case series used 810 nm pulsed (10 Hz) transcranial plus intranasal LED devices targeting default mode network nodes. After 12 weeks, patients with mild-to-moderately severe dementia showed significant gains on the Mini-Mental State Examination (MMSE) and ADAS-cog, along with reports of better sleep, reduced anxiety, fewer angry outbursts, and improved function. Benefits faded during a subsequent no-treatment period. PubMed Article Here!
A 2021 randomized trial of transcranial near-infrared stimulation (twice daily for 8 weeks) in mild-to-moderate dementia reported average MMSE improvements of about 4.8 points, gains on logical memory, trail-making, naming, and verbal learning tests, plus caregiver observations of better mood, energy, sleep, and daily routine.
Systematic reviews of preclinical and early clinical studies (including one covering literature through 2020) found positive results across nearly all included papers, though clinical trials were often small, sometimes lacked robust controls, and used varied parameters. Recent meta-analyses of photobiomodulation for cognitive function also report moderate benefits for global cognition, working memory, attention, and executive function, particularly in people with existing impairment. Dementia Review from 2026.
Neurological Benefits: ADHD and Attention/Working Memory
Emerging clinical data specifically address ADHD. A 2025 study of 48 adults with ADHD used repetitive transcranial photobiomodulation (1064 nm laser, 250 mW/cm², 720 seconds daily for 7 days targeting relevant cortical areas). Participants showed significant improvements in working memory (N-back tasks) and sustained attention (Continuous Performance Test), with peak effect sizes (Cohen’s d 0.84–1.26) at 2–3 weeks post-intervention. Lower baseline performance predicted larger gains, and the intervention was well-tolerated (mild, transient side effects in a small percentage).
Additional randomized work has linked 1064 nm tPBM to improved prefrontal oxygenation (measured by fNIRS) and better impulse control/correct rejections on continuous performance tasks in adults with ADHD, bringing performance closer to non-ADHD levels in some measures. Animal models of ADHD-like symptoms have also shown reduced impulsivity/hyperactivity alongside lower neuroinflammation and preserved myelin integrity after PBMT. A peer review article from 2026 is HERE!
Broader cognitive studies in healthy adults and those with mild cognitive impairment similarly report gains in attention, working memory, and executive function after tPBM.
Neurological Benefits: Traumatic Brain Injury, Parkinson’s, Mood, and Other Areas
Chronic mild TBI studies (including LED protocols with red + NIR wavelengths) have reported improvements in executive function, verbal learning/memory, sleep, and reductions in post-concussion and PTSD-related symptoms, sometimes with accompanying increases in regional cerebral blood flow on imaging.
Parkinson’s research includes both motor and non-motor outcomes; some trials and case series note benefits for motor signs, cognition, sleep, and quality of life with transcranial and/or systemic application, though results are mixed and evidence quality is still low-to-moderate. Here is a direct study on PD.
Depression, anxiety, and related symptoms appear in several tPBM reports, with mechanisms involving mitochondrial support, increased cerebral blood flow, and BDNF modulation. Autism spectrum studies and other neurodevelopmental applications remain very early. Healthy older adults have shown improvements in working memory and cognitive inhibition in some trials.
Practical Considerations and Caveats
Effective parameters vary by study: common wavelengths include ~810 nm and 1064–1080 nm; both continuous and pulsed (e.g., 10 Hz or 40 Hz) modes appear; delivery can be transcranial (helmets, panels, lasers), intranasal, or combined. Dose (irradiance, fluence, session duration/frequency) matters—biphasic dose responses exist, so more is not always better. Many promising protocols use relatively low-to-moderate irradiance with repeated sessions over weeks.
Limitations are important. Most clinical studies are small, heterogeneous in design and parameters, and some lack sham controls or long-term follow-up. Systematic reviews rate evidence certainty as moderate for certain Alzheimer’s cognition outcomes under higher-irradiance conditions, and lower or very low for other indications. PBMT is not FDA-approved as a treatment for dementia, ADHD, or most neurological conditions discussed here. Results should not replace standard medical care.
At Exalt Recovery, we view photobiomodulation as a promising supportive modality within a broader recovery and brain-health framework. Anyone considering it should consult a qualified healthcare provider, especially if they have photosensitivity concerns, active cancer, or are taking photosensitizing medications.
Frequently Asked Questions
Is red light therapy / PBMT safe for the brain?
Published clinical studies report a favorable safety profile. Mild, transient effects (e.g., slight headache or warmth) occur infrequently. No serious adverse events linked to properly dosed transcranial protocols appear in the reviewed literature. Eye protection is typically used with higher-power devices, and medical supervision is recommended.
How is it different from just sitting in the sun or using a regular red light bulb?
Therapeutic PBMT uses specific wavelengths (especially in the NIR window that penetrates tissue and skull more effectively), controlled irradiance, and often pulsed delivery at defined doses and treatment sites. Everyday light sources lack this precision and typically do not deliver the energy densities studied for neurological effects.
Can it help with focus or ADHD symptoms?
Early human data are promising. The 2025 Lai et al. study and related work showed measurable improvements in working memory and attention tasks in adults with ADHD after short courses of 1064 nm tPBM, with effects lasting into follow-up weeks. Larger, longer trials are still needed before firm clinical recommendations can be made.
Does the research support using it for dementia or Alzheimer’s?
Animal data are strong and mechanistic. Small human trials and case series (including Saltmarche 2017 and Nizamutdinov 2021) show cognitive and functional gains during treatment periods. Systematic reviews describe the clinical evidence as preliminary but consistently positive and call for larger randomized trials. It is best viewed as an investigational supportive approach, not a disease-modifying treatment at this stage.